



Child ADHD Medication Follow-up (*Initiation*)

Measure Type: HEDIS (claims) / Age Cohort: 6–12 years of age as of the Index Prescription Start Date (IPSD)

Measure Definition

Percent of patients* with an ambulatory prescription dispensed for ADHD medication, who had one follow-up visit with practitioner with prescribing authority** during the 30-day Initiation Phase

* **Patients** are identified as “new”, dispensed an ADHD medication for the first time or “existing”, patient has a history of taking ADHD medication but had no ADHD medication dispensed for either new or refill prescription in a period of 120 days or more.

****Prescribing Authority:** A practitioner with prescribing privileges, including physicians, nurse practitioners, physician assistants who have the authority to prescribe medications

Documentation Required

Index visit resulting with ADHD diagnosis and ADHD medication prescribed ([Medication List C](#))

- Follow-up visit within 30 days of the index visit

Applicable Follow-up Visit:

- **CPT/HCPCS Codes:** 90791, 90792, 90832-90845, 90847-90853, 90875, 90876, 96150-96154, 98960-98962, 99078, 99201-99215, 99217-99223, 99231-99233, 99238, 99239, 99241-99245, 99251- 99255, 99341-99350, 99383, 99384, 99393, 99394, 99401-99404, 99411-99412, 99510, H0034, M0064, H0002

Role of Care Management

- Ensure prescription fill
- Ensure follow-up visit within 30 days
- Identify & address barriers to adherence

Role of PCP Practice

- Schedule follow-up visit within 30 days of index visit OR referral to behavioral health prescribing provider
- Visit reminder message to the patient



Child ADHD Medication Follow-up (*Continuation*)

Measure Type: HEDIS (claims) / Age Cohort: 6–12 years of age as of the Index Prescription Start Date (IPSD)

Measure Definition

Percent of patients with an ambulatory prescription dispensed for ADHD medication, who remained on the medication for at least 210 days and who, in addition to the first follow-up visit in the Initiation Phase, had at **least two follow-up visits with any practitioner** within 270 days (9 months) after the Initiation Phase ended.

Documentation Required

Index visit resulting with ADHD diagnosis and ADHD medication prescribed ([Medication List C](#))

- One follow-up visit within 30 days of the index visit
- Two follow-up visits after the initiation phase but within 270 days
 - Visits must be on different dates of service
 - Only one of the two visits may be a telephone visit or a telehealth visit
- Refill of prescriptions

Applicable Follow-up Visit:

- **CPT/HCPCS Codes:** 90791, 90792, 90832-90845, 90847-90853, 90875, 90876, 96150-96154, 98960- 98962, 99078, 99201-99215, 99217-99223, 99231-99233, 99238, 99239, 99241-99245, 99251-99255, 99341-99350, 99383, 99384, 99393, 99394, 99401-99404, 99411, 99412, 99510, G0155, G0176, G0177, G0409-G0411, G0463, H0002, H0004, H0031, H0034-H0037, H0039, H0040, H2000, H2001, H2010-H2020, M0064, S0201, S9480, S9484, S9485, T1015
- **Telephone Visit CPT Codes:** 98966-98968, 99441-99443
- **Telehealth Modifier Codes:** GT, 95

Role of Care Management

- Verify diagnosis with patient
- Ensure consistent refills
- Ensure follow-up visits
- Identify & address barriers to adherence

Role of PCP Practice

- Schedule two additional follow-up visits within 270 days OR ensure two additional follow-up visits with behavioral health provider
- Visit reminder message to the patient



Suffolk Care
Collaborative

MEASURE MEDICATION LISTS



Child ADHD Medication Follow-up

[Back to Measure](#) – Initiation

[Back to Measure](#) – Continuation



| Description | Prescription |
|---------------------------------------|---|
| CNS stimulants | <ul style="list-style-type: none">• Amphetamine-dextroamphetamine• Dexmethylphenidate• Dextroamphetamine• Lisdexamfetamine• Methylphenidate• Methamphetamine |
| Alpha-2 receptor agonists | <ul style="list-style-type: none">• Clonidine• Guanfacine |
| Miscellaneous ADHD medications | <ul style="list-style-type: none">• Atomoxetine |